Merus N.V.

Company Listings from SPi: Merus N.V.

You are here: Home >> SPi Company Listings >> Merus N.V.

 

Merus N.V.

Website:
http://

Search for other references to "merus" on SPi News

Latest Merus N.V. News

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology com...... 13:35 GMT Friday 10th August 2018

Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference UTRECHT, The Netherlands, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Tuesday 7th August 2018

Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 - Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128's unique mechanism of action published in the scientific journal...... 12:00 GMT Thursday 26th July 2018

Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 UTRECHT, The Netherlands, July 26, 2018 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology c...... 12:00 GMT Thursday 26th July 2018

Merus Announces Annual Meeting of Shareholders UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody thera...... 09:00 GMT Thursday 5th July 2018

Merus Announces Annual Meeting of Shareholders UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 09:00 GMT Thursday 5th July 2018

Merus to Present at the Jefferies 2018 Healthcare Conference UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therap...... 12:00 GMT Thursday 31st May 2018

Merus to Present at the Jefferies 2018 Healthcare Conference UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeuti...... 12:00 GMT Thursday 31st May 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors - IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology c...... 12:00 GMT Thursday 24th May 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeuti...... 12:00 GMT Thursday 24th May 2018

Buy Merus N.V.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers